This site uses optional cookies which are currently not set, but will be if you visit another page. Find out more about the cookies we use


Bionow members are welcome to submit PR items to this newsroom for all to see. An animated website user guide is available here which demonstrates how members can add news directly to the website after logging in. 

Whether currently a member or not, to keep in touch with all relevant news and information make sure you are registered to receive our newsletter.


Professor John Tidy presents key HPV data at AOGIN 2017

17 October 2017

Zilico’s clinical founder Professor John Tidy will be speaking at this year’s AOGIN event, joined with the 2nd meeting of the Japan HPV Society, being held this week (18th-19th October) in Tokyo, Japan.

> Read More


Funding competition - Establishing a UK vaccines development and manufacturing centre

16 October 2017

UK-based organisations can apply for up to £66 million to build and establish a national vaccines development and manufacturing centre.

> Read More


Gendius announces funding from Catapult Ventures to launch innovative digital health platform for patients living with diabetes

10 October 2017

Gendius, a digital health start-up developing a solution for patients living with diabetes to better manage their condition, today announced the completion of a Series A funding to launch Intellin® - an App based platform for people living with diabetes. The funding came from the GM&C Life Sciences Fund, managed by Catapult Ventures.

> Read More


Data protection: patient confidentiality in the age of AI

6 October 2017

Thinking inside the box: the intelligent diagnostic device By: Giangiacomo Olivi, Gareth Stokes and Bonella Ramsay

> Read More


AMR Centre Medivir deal targets ‘superbug’ time-bomb

6 October 2017

Alderley Park, England, and Stockholm, Sweden - Medivir AB (Nasdaq Stockholm: MVIR) and AMR Centre Ltd (AMRC) today announce signing of an agreement providing AMRC the exclusive worldwide rights to Medivir’s research stage metallo-ß-lactamase inhibitor (MBLI) program.

> Read More